Invesco V.I. Health Care Fund
AIM Variable Insurance Funds (Invesco Variable Insurance Funds)
Expense ratio
Net assets1
$148.42M
Holdings1
82
Category
US Equity
Return

Investment objective & strategy

As of April 29, 2025 · prospectus

Objective. The Funds investment objective is long-term growth of capital.

Strategy. The Fund invests, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities. The Fund will concentrate its investments in the securities of domestic and foreign issuers in the health care industry. The Fund uses various criteria to determine whether an issuer is engaged in health care-related industries, including whether (1) it derives 50% or more of its gross income or its net sales from activities in the health care industry; (2) it devotes 50% or more of its assets to producing revenues from the health care industry; or (3) … The Fund invests, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities. The Fund will concentrate its investments in the securities of domestic and foreign issuers in the health care industry. The Fund uses various criteria to determine whether an issuer is engaged in health care-related industries, including whether (1) it derives 50% or more of its gross income or its net sales from activities in the health care industry; (2) it devotes 50% or more of its assets to producing revenues from the health care industry; or (3) based on other available information, the Funds portfolio manager determines that its primary business is within the health care industry. Such other available information may include industry classifications from any one or more third-party providers, such as those using the Global Industry Classification Standard (GICS ), the North American Industry Classification System (NAICS), or the Bloomberg Industry Classification System (BICS). Issuers engaged in health care-related industries include those that design, provide, distribute, manufacture, or sell products or services used for or in connection with health care or medicine (such as pharmaceutical issuers, biotechnology research firms, companies that make or sell medical products, and companies that own or operate health care facilities and systems). The Fund invests primarily in equity securities, including common and preferred stock, and depositary receipts. The Fund may invest in the securities of issuers of all capitalization sizes and may invest a significant amount of its net assets in the securities of small- and mid-capitalization issuers. The Fund may invest in securities of foreign issuers including up to 20% of its net assets in securities of issuers located in emerging markets countries, i.e., those that are generally in the early stages of their industrial cycles. The Fund can invest in derivative instruments, including forward foreign currency contracts. The Fund can use forward foreign currency contracts to hedge against adverse movements in the foreign currencies in which portfolio securities are denominated. In selecting securities for the Fund, the portfolio manager uses a research-oriented bottom-up investment approach, focusing on issuer fundamentals and the strength of an individual issuer before considering the impact of overall economic, market, sector or industry trends. This approach includes analysis of a company's financial statements and management structure and consideration of the company's operations, product development, and its industry position. The portfolio manager currently focuses on companies that the portfolio manager believes are characterized by industry leadership, market share growth, high caliber management teams, sustainable competitive advantages, and strong growth themes or new innovative products or services. The portfolio manager monitors individual issuers for changes in the factors above, which may trigger a decision to sell a security, but does not require a decision to do so. The factors considered by the portfolio manager may vary in particular cases and may change over time.

Top holdings

As of March 31, 2026 · N-PORT
SecurityTickerValue% of fund
LILLY ELI and CO $13.57M 9.14%
JOHNSON&JOHNSON $8.63M 5.81%
AstraZeneca PLC ORD USD0.25 AZN LN $6.47M 4.36%
GILEAD SCIENCES INC $6.11M 4.12%
ABBVIE INC $5.52M 3.72%
CENCORA INC $5.42M 3.65%
MCKESSON CORP $5.35M 3.61%
ARGENX SE SPONSORED ADR $5.03M 3.39%
Invesco Private Prime Fund $4.28M 2.89%
Invesco Treasury Portfolio, Institutional Class $3.68M 2.48%
View all holdings →

Allocation by sector

As of March 31, 2026 · N-PORT
View portfolio breakdown →

Portfolio moves

Dec 31, 2025 → Mar 31, 2026
Opened
15
Exited
12
Increased
21
Decreased
45
Unchanged
1

How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.

View portfolio moves →

Similar funds

Funds whose portfolios most overlap this one, by weight
FundOverlapNet exp.
Invesco Health Care Fund · GGHCX, GTHCX, GTHIX, GGHYX, GTHRX 79% 0.72%
Health Sciences Trust · JAFMX, JEHSX, JAFKX 52% 0.84%
EQ/T.Rowe Price Health Sciences Portfolio 50% 0.95%
View all similar funds →

Advisers

As of December 31, 2025 · N-CEN
FirmRole
Invesco Advisers, Inc. Adviser
Invesco Capital Management LLC Sub-adviser
Invesco Senior Secured Management, Inc. Sub-adviser
Invesco Asset Management (Japan) Ltd. Sub-adviser
Invesco Hong Kong Ltd. Sub-adviser
Invesco Asset Management Ltd. Sub-adviser
Invesco Canada Ltd. Sub-adviser
Invesco Management S.A. Sub-adviser

Footnotes

  1. Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.

Machine-readable: JSON · Markdown. Programmatic access via the agent surface.